Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

That was the number that I had in my head too, but I was concerned I was conflating that with the "low-double digits royalty" on Rida sales in the Merck deal.

We'll see what BLCM prices out at and what kind of IPO premium the trading market gives it.

It looks like Araid did take a haircut on its exit, but perhaps not a bath. Of course, if BLCM really does cure GvH, then Ariad will not look good in hindsight, but the company's horizon is currently too short for that kind of thinking.